SAN DIEGO--(BUSINESS WIRE)-- DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today that Stelo, the first over-the-counter ...

Join the event trusted by enterprise leaders for nearly two decades. VB Transform brings together the people building real enterprise AI strategy. Learn more About one in three Americans, or 125 ...

In March, the FDA approved DexCom Inc‘s (NASDAQ:DXCM) Stelo Glucose Biosensor System as the first over-the-counter (OTC) continuous glucose monitor (CGM). The Dexcom Stelo Glucose Biosensor System is ...

Credit: Dexcom. Stelo is an integrated CGM that continuously measures, records, analyzes, and displays glucose values in individuals 18 years of age and older who are not on insulin. Dexcom’s Stelo ...

SAN FRANCISCO, June 23, 2025 /PRNewswire/ -- Stelo, an enterprise software company, has filed suit in Federal District Court for the Central District of California against San Diego-based Dexcom, Inc.

I’ve always considered myself a somewhat healthy person, especially after I gave up smoking and vaping a few years ago. Unfortunately, that proved incorrect. Three years ago, I had a near-constant ...

This week, Dexcom became the first medical device company to integrate generative AI into a continuous glucose monitor. The company added generative AI to its Stelo glucose monitor, which it began ...

After getting the green light from the FDA back in March, Dexcom today launched its first over-the-counter wearable continuous glucose biosensor, Stelo, in the U.S. market. The device is now available ...

DexCom Inc. DXCM recently announced the availability of Stelo, the first over-the-counter (OTC) continuous glucose monitoring (CGM) biosensor in the United States. The biosensor is available for ...

Dexcom on Tuesday announced its first generative AI feature for its Stelo biosensor that gives users a personalized weekly report about their glucose. The company has been building a generative AI ...